Agents central to psoriasis or PsA management—such as TNF inhibitors and IL-17 inhibitors—may be associated with photosensitive rashes, de novo CLE, drug-induced lupus, or SLE exacerbations in susceptible individuals [10,18,26,27,28,29,30,31,33,34,38,42,43,44]. Here, IL17A is linked to systemic lupus erythematosus.